Regulus Therapeutics Company Profile (NASDAQ:RGLS)

About Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics logoRegulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:RGLS
  • CUSIP: 75915K10
  • Web:
  • Market Cap: $135.96 million
  • Outstanding Shares: 103,785,000
Average Prices:
  • 50 Day Moving Avg: $1.01
  • 200 Day Moving Avg: $1.23
  • 52 Week Range: $0.79 - $3.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.47
  • P/E Growth: -0.03
Sales & Book Value:
  • Annual Revenue: $257,999.00
  • Price / Sales: 526.97
  • Book Value: $0.38 per share
  • Price / Book: 3.45
  • EBIDTA: ($73,960,000.00)
  • Net Margins: -31,460.47%
  • Return on Equity: -173.20%
  • Return on Assets: -90.45%
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 4.49%
  • Quick Ratio: 4.49%
  • Average Volume: 838,206 shs.
  • Beta: 1.6
  • Short Ratio: 3.95

Frequently Asked Questions for Regulus Therapeutics (NASDAQ:RGLS)

What is Regulus Therapeutics' stock symbol?

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

How were Regulus Therapeutics' earnings last quarter?

Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.10. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. View Regulus Therapeutics' Earnings History.

When will Regulus Therapeutics make its next earnings announcement?

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Regulus Therapeutics.

Where is Regulus Therapeutics' stock going? Where will Regulus Therapeutics' stock price be in 2017?

6 brokerages have issued 12-month price objectives for Regulus Therapeutics' stock. Their predictions range from $1.00 to $9.00. On average, they expect Regulus Therapeutics' share price to reach $4.10 in the next twelve months. View Analyst Ratings for Regulus Therapeutics.

What are analysts saying about Regulus Therapeutics stock?

Here are some recent quotes from research analysts about Regulus Therapeutics stock:

  • 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (9/19/2017)
  • 2. Needham & Company LLC analysts commented, "Regulus provided a 2Q17 corporate update yesterday. RG-012 Phase 2 trial protocols have been submitted to FDA, sites have been selected, and enrollment is expected to begin soon. Mgmt reiterated guidance for biomarker data 4Q17 and interim clinical efficacy data mid-2018, followed by final results YE18. Mgmt also reiterated plans for an IND submission for RGLS4326, in development for Autosomal Dominant Polycystic Kidney Disease, by YE17. As a reminder, several programs were discontinued in Jun 2017. Company efforts are now directed primarily to the two lead programs, although a microRNA R&D effort remains underway." (8/2/2017)
  • 3. Wedbush analysts commented, "RGLS reported Q4/FY16 revenues of $0.02MM/$1.2MM vs. consensus estimates of $0.2MM/$1.4MM and GAAP EPS (loss) of $(0.38)/$(1.55) vs. consensus estimates of $(0.34)/$(1.52). RGLS ended 2016 with cash and cash equivalents of $76.1MM, which we project to provide cash runway into mid:18 aligned with guidance... Following completion of the multiple ascending dose (MAD) study of RG-012 in healthy volunteers in Q2:17, RGLS is planning to initiate a Phase 1/2 renal biopsy study in AS patients that will evaluate RG-012 tissue PK, target engagement, and effects on disease biomarkers. We believe positive results in-line with RGLS' preclinical data could be indicative of future success." (3/6/2017)
  • 4. Cowen and Company analysts commented, "Regulus reported Q4 earnings and provided a pipeline update." (3/3/2017)
  • 5. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on RGLS stock, but we are lowering our PT by $4 to $7, as a result of a reduction in our pTS estimate for the RG-101 program from 50% to 25%. We believe that "platform buyers" could still be attracted to the stock, but that investors seeking commercial proof of concept may have been put somewhat at bay given the delay in the FDA lift of the clinical trial hold for RG-101 as a treatment for infection with the HCV." (3/3/2017)

Are investors shorting Regulus Therapeutics?

Regulus Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,529,089 shares, an increase of 32.7% from the August 15th total of 2,660,204 shares. Based on an average daily trading volume, of 552,900 shares, the short-interest ratio is currently 6.4 days. Approximately 4.6% of the company's shares are sold short.

Who are some of Regulus Therapeutics' key competitors?

Who are Regulus Therapeutics' key executives?

Regulus Therapeutics' management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Chairman of the Board
  • Joseph P. Hagan, President, Chief Executive Officer, Principal Executive Officer, Director
  • Daniel Chevallard, Chief Financial Officer, Principal Financial and Accounting Officer
  • Mark Deeg, Chief Medical Officer
  • B. Lynne Parshall J.D., Director
  • Douglas E. Williams Ph.D., Director
  • David Baltimore Ph.D., Independent Director
  • Mark G. Foletta CPA, Independent Director
  • William H. Rastetter Ph.D., Independent Director

Who owns Regulus Therapeutics stock?

Regulus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), EcoR1 Capital LLC (3.57%), Vanguard Group Inc. (2.76%), South Dakota Investment Council (2.50%), Wells Fargo & Company MN (1.31%) and Goldman Sachs Group Inc. (0.35%). Company insiders that own Regulus Therapeutics stock include Alnylam Pharmaceuticals, Inc, Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.

Who sold Regulus Therapeutics stock? Who is selling Regulus Therapeutics stock?

Regulus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and Vanguard Group Inc.. View Insider Buying and Selling for Regulus Therapeutics.

Who bought Regulus Therapeutics stock? Who is buying Regulus Therapeutics stock?

Regulus Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Goldman Sachs Group Inc., LMR Partners LLP, GSA Capital Partners LLP, Quantitative Investment Management LLC, FMR LLC, Royal Bank of Canada and Wedbush Securities Inc.. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.

How do I buy Regulus Therapeutics stock?

Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regulus Therapeutics' stock price today?

One share of Regulus Therapeutics stock can currently be purchased for approximately $1.31.

MarketBeat Community Rating for Regulus Therapeutics (NASDAQ RGLS)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  414
MarketBeat's community ratings are surveys of what our community members think about Regulus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $4.10 (212.98% upside)

Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/7/2017WedbushReiterated RatingOurperform$4.00MediumView Rating Details
8/2/2017Needham & Company LLCReiterated RatingHoldHighView Rating Details
8/2/2017Chardan CapitalDowngradeBuy -> NeutralLowView Rating Details
6/12/2017BMO Capital MarketsSet Price TargetHold$1.00LowView Rating Details
3/3/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
3/3/2017Cantor FitzgeraldLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
1/30/2017Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
6/28/2016FBR & CoReiterated RatingOutperform$30.00 -> $9.00N/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Regulus Therapeutics (NASDAQ:RGLS)
Earnings by Quarter for Regulus Therapeutics (NASDAQ:RGLS)
Earnings History by Quarter for Regulus Therapeutics (NASDAQ RGLS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017($0.19)N/AView Earnings Details
8/1/2017Q2 2017($0.31)($0.41)$0.02 million$0.02 millionViewListenView Earnings Details
3/2/2017Q4 2016($0.37)($0.38)$0.20 million$0.02 millionViewListenView Earnings Details
8/2/2016Q216($0.38)($0.40)$0.50 million$0.48 millionViewListenView Earnings Details
5/2/2016Q1($0.33)($0.40)$2.25 million$0.49 millionViewListenView Earnings Details
2/22/2016Q415($0.25)($0.14)$5.09 million$10.90 millionViewListenView Earnings Details
11/5/2015Q315($0.37)($0.25)$3.57 million$1.87 millionViewN/AView Earnings Details
8/4/2015Q215($0.29)($0.41)$2.40 million$3.80 millionViewN/AView Earnings Details
5/7/2015($0.26)($0.25)$3.38 million$4.20 millionViewListenView Earnings Details
2/18/2015($0.21)($0.47)$2.24 million$4.22 millionViewListenView Earnings Details
11/5/2014($0.23)($0.23)$2.76 million$1.08 millionViewListenView Earnings Details
8/6/2014Q214($0.19)($0.29)$3.20 million$0.74 millionViewN/AView Earnings Details
5/8/2014($0.14)($0.30)$3.80 million$1.63 millionViewN/AView Earnings Details
2/27/2014($0.13)($0.11)ViewN/AView Earnings Details
8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView Earnings Details
2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView Earnings Details
11/19/2012Q312($15.98)$3.81 million$2.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Regulus Therapeutics (NASDAQ:RGLS)
2017 EPS Consensus Estimate: ($0.79)
2018 EPS Consensus Estimate: ($0.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.26)($0.26)($0.26)
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.13)($0.13)($0.13)
Q1 20181($0.12)($0.12)($0.12)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.12)($0.12)($0.12)
Q4 20181($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)


Dividend History for Regulus Therapeutics (NASDAQ:RGLS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Regulus Therapeutics (NASDAQ:RGLS)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 21.92%
Insider Trades by Quarter for Regulus Therapeutics (NASDAQ:RGLS)
Institutional Ownership by Quarter for Regulus Therapeutics (NASDAQ:RGLS)
Insider Trades by Quarter for Regulus Therapeutics (NASDAQ:RGLS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Daniel R ChevallardCFOBuy54,945$0.91$49,999.95View SEC Filing  
7/25/2017Joseph P HaganInsiderBuy219,780$0.91$199,999.80View SEC Filing  
7/25/2017William H RastetterDirectorBuy274,725$0.91$249,999.75View SEC Filing  
3/22/2017Stelios PapadopoulosDirectorBuy500,000$1.22$610,000.00View SEC Filing  
3/7/2017William H RastetterDirectorBuy250,000$1.15$287,500.00View SEC Filing  
3/3/2016Joseph P HaganCOOBuy10,000$7.19$71,900.00View SEC Filing  
2/23/2016Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,000,000$7.18$7,180,000.00View SEC Filing  
7/21/2015William H RastetterDirectorBuy100,000$10.17$1,017,000.00View SEC Filing  
7/20/2015William H RastetterDirectorBuy38,765$10.13$392,689.45View SEC Filing  
7/17/2015Isis Pharmaceuticals IncMajor ShareholderSell343,133$10.60$3,637,209.80View SEC Filing  
4/21/2015Kleanthis G XanthopoulosCEOSell200,000$17.15$3,430,000.00View SEC Filing  
4/13/2015Bruce L A CarterDirectorSell20,000$17.66$353,200.00View SEC Filing  
3/5/2015Kleanthis G XanthopoulosCEOSell89,230$20.26$1,807,799.80View SEC Filing  
2/2/2015Kleanthis G XanthopoulosCEOSell5,700$19.61$111,777.00View SEC Filing  
1/29/2015Kleanthis G XanthopoulosCEOSell145,000$18.06$2,618,700.00View SEC Filing  
1/28/2015Neil W GibsonInsiderSell80,000$18.05$1,444,000.00View SEC Filing  
11/28/2014Neil W GibsonInsiderSell2,500$19.30$48,250.00View SEC Filing  
11/3/2014Isis Pharmaceuticals IncMajor ShareholderSell1,279,411$15.94$20,393,811.34View SEC Filing  
10/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell113,084$14.02$1,585,437.68View SEC Filing  
10/22/2014Neil W GibsonInsiderSell3,300$14.44$47,652.00View SEC Filing  
10/10/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,000$6.41$12,820.00View SEC Filing  
10/10/2014Isis Pharmaceuticals IncDirectorSell10,050$6.56$65,928.00View SEC Filing  
10/9/2014Isis Pharmaceuticals IncDirectorSell4,750$6.58$31,255.00View SEC Filing  
10/8/2014Isis Pharmaceuticals IncDirectorSell3,300$6.63$21,879.00View SEC Filing  
10/3/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell10,300$6.74$69,422.00View SEC Filing  
10/3/2014Isis Pharmaceuticals IncDirectorSell3,300$6.88$22,704.00View SEC Filing  
10/2/2014Isis Pharmaceuticals IncDirectorSell3,750$6.64$24,900.00View SEC Filing  
10/1/2014Isis Pharmaceuticals IncDirectorSell3,250$6.71$21,807.50View SEC Filing  
9/30/2014Kleanthis G XanthopoulosCEOSell2,300$7.02$16,146.00View SEC Filing  
9/26/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.04$17,600.00View SEC Filing  
9/26/2014Isis Pharmaceuticals IncDirectorSell8,750$7.13$62,387.50View SEC Filing  
9/25/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$7.12$17,800.00View SEC Filing  
9/24/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,750$7.19$26,962.50View SEC Filing  
9/19/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell7,700$7.31$56,287.00View SEC Filing  
9/19/2014Isis Pharmaceuticals IncDirectorSell4,100$7.22$29,602.00View SEC Filing  
9/18/2014Isis Pharmaceuticals IncDirectorSell1,500$7.40$11,100.00View SEC Filing  
9/17/2014Isis Pharmaceuticals IncDirectorSell2,100$7.43$15,603.00View SEC Filing  
9/12/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell8,900$7.85$69,865.00View SEC Filing  
9/12/2014Isis Pharmaceuticals IncDirectorSell3,500$7.96$27,860.00View SEC Filing  
9/12/2014Neil W GibsonInsiderSell4,200$8.01$33,642.00View SEC Filing  
9/11/2014Isis Pharmaceuticals IncDirectorSell3,400$7.83$26,622.00View SEC Filing  
9/10/2014Isis Pharmaceuticals IncDirectorSell2,000$7.70$15,400.00View SEC Filing  
9/5/2014Isis Pharmaceuticals IncDirectorSell10,050$7.07$71,053.50View SEC Filing  
8/29/2014Isis Pharmaceuticals IncDirectorSell1,500$6.84$10,260.00View SEC Filing  
8/28/2014Isis Pharmaceuticals IncDirectorSell2,000$6.96$13,920.00View SEC Filing  
8/28/2014Kleanthis G XanthopoulosCEOSell3,505$7.06$24,745.30View SEC Filing  
8/27/2014Isis Pharmaceuticals IncDirectorSell1,500$7.21$10,815.00View SEC Filing  
8/22/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell5,250$6.75$35,437.50View SEC Filing  
8/21/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,500$6.89$17,225.00View SEC Filing  
8/20/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell3,000$7.14$21,420.00View SEC Filing  
8/15/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,450$6.98$10,121.00View SEC Filing  
8/14/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell1,750$7.04$12,320.00View SEC Filing  
8/13/2014Alnylam Pharmaceuticals, Inc.Major ShareholderSell2,250$7.02$15,795.00View SEC Filing  
8/8/2014Isis Pharmaceuticals IncDirectorSell1,850$6.80$12,580.00View SEC Filing  
8/7/2014Isis Pharmaceuticals IncDirectorSell2,600$6.66$17,316.00View SEC Filing  
8/6/2014Isis Pharmaceuticals IncDirectorSell3,150$7.08$22,302.00View SEC Filing  
8/1/2014Isis Pharmaceuticals IncDirectorSell2,600$6.21$16,146.00View SEC Filing  
7/31/2014Isis Pharmaceuticals IncDirectorSell1,750$6.42$11,235.00View SEC Filing  
7/30/2014Isis Pharmaceuticals IncDirectorSell1,000$6.60$6,600.00View SEC Filing  
7/25/2014Isis Pharmaceuticals IncDirectorSell1,700$6.55$11,135.00View SEC Filing  
7/24/2014Isis Pharmaceuticals IncDirectorSell1,850$6.81$12,598.50View SEC Filing  
7/23/2014Isis Pharmaceuticals IncDirectorSell1,700$6.88$11,696.00View SEC Filing  
7/18/2014Isis Pharmaceuticals IncDirectorSell5,000$6.80$34,000.00View SEC Filing  
7/17/2014Isis Pharmaceuticals IncDirectorSell5,000$6.58$32,900.00View SEC Filing  
7/16/2014Isis Pharmaceuticals IncDirectorSell3,500$6.59$23,065.00View SEC Filing  
7/11/2014Isis Pharmaceuticals IncDirectorSell1,750$6.48$11,340.00View SEC Filing  
7/10/2014Isis Pharmaceuticals IncDirectorSell4,500$6.69$30,105.00View SEC Filing  
7/9/2014Isis Pharmaceuticals IncDirectorSell1,800$7.08$12,744.00View SEC Filing  
2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View SEC Filing  
1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View SEC Filing  
1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View SEC Filing  
1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View SEC Filing  
1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View SEC Filing  
10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Regulus Therapeutics (NASDAQ:RGLS)
Latest Headlines for Regulus Therapeutics (NASDAQ:RGLS)
DateHeadline logoRegulus Therapeutics Inc. (RGLS) Upgraded at Zacks Investment Research - September 16 at 8:20 AM logoRegulus Therapeutics Inc. (RGLS) Sees Significant Increase in Short Interest - September 16 at 1:20 AM logoRegulus Therapeutics Inc. (RGLS) Receives Consensus Rating of "Hold" from Analysts - September 2 at 10:40 AM logoRegulus to Present at the 2017 Wells Fargo Healthcare Conference - August 31 at 9:25 AM logoRegulus Therapeutics Inc. (RGLS) Short Interest Update - August 29 at 1:06 AM logoAre Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? - Nasdaq - August 26 at 8:50 AM logoAre Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? - August 25 at 10:53 AM logoBrokers Issue Forecasts for Regulus Therapeutics Inc.'s Q3 2017 Earnings (NASDAQ:RGLS) - August 9 at 7:28 AM logoRegulus to Present at the 2017 Wedbush PacGrow Healthcare Conference - August 9 at 6:56 AM logoRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Recommendation of "Hold" by Brokerages - August 8 at 11:04 AM logoRegulus Therapeutics Inc. (RGLS) Earns "Ourperform" Rating from Wedbush - August 7 at 11:20 AM logoRegulus Therapeutics' (RGLS) Hold Rating Reaffirmed at Needham & Company LLC - August 2 at 4:38 PM logoRegulus Therapeutics Inc. (RGLS) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS - August 2 at 12:40 PM logoRegulus Therapeutics' (RGLS) CEO Jay Hagan on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha - August 2 at 7:11 AM logoInvestor Network: Regulus Therapeutics Inc. to Host Earnings Call - August 2 at 7:10 AM logoRegulus Reports Second Quarter 2017 Financial Results and Recent Events - August 2 at 7:10 AM logoRegulus reports 2Q loss - August 2 at 7:10 AM logoEdited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT - August 2 at 7:10 AM logoRegulus Therapeutics Inc. Forecasted to Earn Q3 2017 Earnings of ($0.10) Per Share (RGLS) - July 31 at 7:39 AM logoRegulus Therapeutics Inc. (NASDAQ:RGLS) to Release Earnings on Tuesday - July 27 at 3:04 PM logoRegulus to Provide Second Quarter 2017 Financial Results on August 1, 2017 - July 26 at 6:46 AM logoRegulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares - July 26 at 6:46 AM logoRegulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares - July 26 at 6:46 AM logoRegulus Therapeutics Inc. (RGLS) Insider Purchases $199,999.80 in Stock - July 25 at 7:51 PM logoRegulus Therapeutics Inc. (NASDAQ:RGLS) CFO Daniel R. Chevallard Buys 54,945 Shares - July 25 at 7:51 PM logoWilliam H. Rastetter Acquires 274,725 Shares of Regulus Therapeutics Inc. (RGLS) Stock - July 25 at 7:28 PM logoDryShips, CH Robinson Slide into Thursday's 52-Week Low Club - 24/7 Wall St. - July 20 at 8:49 PM logo28 Stocks Moving In Thursday's Pre-Market Session - Benzinga - July 20 at 3:48 PM logoRegulus Therapeutics (RGLS) Announces 44M Share Common Offering - - July 20 at 3:48 PM logoRegulus Announces Commencement of Public Offering of Common Stock - July 20 at 7:11 AM logoRegulus Announces Pricing of Public Offering of Common Stock - July 20 at 7:11 AM logoRegulus Therapeutics Inc. (NASDAQ:RGLS) Cut to Hold at Zacks Investment Research - July 19 at 9:15 AM logoRegulus Therapeutics Inc. (RGLS) Receives Average Recommendation of "Hold" from Analysts - July 14 at 2:10 PM logoFY2018 Earnings Estimate for Regulus Therapeutics Inc. (RGLS) Issued By Cantor Fitzgerald - June 26 at 7:51 AM logoRegulus Therapeutics Inc. (RGLS) Receives Average Rating of "Hold" from Brokerages - June 19 at 10:32 AM logoChardan Capital Cuts Regulus Therapeutics Inc. (RGLS) Price Target to $2.50 - June 18 at 6:20 PM logoRegulus Therapeutics (RGLS) Promotes Mark Deeg to CMO - June 14 at 12:37 AM logoRegulus Therapeutics (RGLS) Promotes Mark Deeg to CMO - - June 13 at 7:36 PM logoChardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations - June 13 at 7:36 PM logoRegulus Therapeutics Inc. (RGLS) Given a $1.00 Price Target at BMO Capital Markets - June 13 at 2:44 PM logoRegulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer - June 13 at 10:05 AM logoRegulus Therapeutics Inc. (RGLS) Given Ourperform Rating at Wedbush - June 13 at 8:28 AM logoBUZZ-U.S. STOCKS ON THE MOVE-GE, Apple, Coherus - June 12 at 8:47 AM logoRegulus Announces Pipeline Updates and Advancements - June 12 at 8:47 AM logoAptuit anuncia un acuerdo de proveedor estratégico con Regulus ... - PR Newswire (Comunicado de prensa) - June 8 at 8:38 AM logoRegulus Therapeutics (RGLS) & Aptuit LLC Announce Strategic Provider Agreement - - June 8 at 8:38 AM logoRegulus Therapeutics Inc (RGLS) Downgraded to Strong Sell at ValuEngine - June 3 at 12:46 PM logoPascale Witz Joins Regulus Board of Directors - June 1 at 9:13 PM logoRegulus Therapeutics Inc (RGLS) Receives "Hold" Rating from BMO Capital Markets - May 29 at 12:38 AM logoRegulus Therapeutics Inc (RGLS) Receives Consensus Recommendation of "Hold" from Analysts - May 23 at 10:02 AM



Regulus Therapeutics (RGLS) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff